Historical record - last NADAC effective date: 10/19/2016
Product Information
MORPHINE SULFATE ER 30 MG CAP is a generic product labeled by Actavis Pharma, Inc., priced at $4.5987 per EA under NDC 00228309011. Its NADAC has been published 179 times since Jun 18, 2014.
FDA first approved this application on Jan 16, 2013.
The High Outlier badge above means this manufacturer's average price in the Morphine sulfate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
30 mg/1
Manufacturer
Actavis Pharma, Inc.NDC
00228309011
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
10/19/2016
Active Ingredients
MORPHINE SULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA079040FDA Approved
1/16/2013
On Market Since
2/4/2014
Pharmacological Classes
Price Statistics
The NADAC for MORPHINE SULFATE ER 30 MG CAP has been published 179 times since Jun 18, 2014, and over the history we have for it it has declined 3.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.5987 per EA |
|---|---|
| All-time high | $4.9125 (Nov 12, 2014) |
| All-time low | $4.4021 (May 18, 2016) |
| Median price | $4.6822 |
| Average price | $4.6632 |
| Largest weekly change | -9.2% (May 18, 2016) |
| Weeks tracked | 179 |
| Tracking since | Jun 18, 2014 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
-3.7%
Last surveyed Nov 15, 2017 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Morphine sulfate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Morphine sulfate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Opioid Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MORPHINE SULFATE ER 30 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for MORPHINE SULFATE ER 30 MG CAP, manufactured by Actavis Pharma, Inc., is $4.5987 per EA (NDC 00228309011), effective Nov 15, 2017.
How has the price of MORPHINE SULFATE ER 30 MG CAP changed over time?
Over the history we have for it, the NADAC for MORPHINE SULFATE ER 30 MG CAP has declined 3.7%. It has been tracked across 179 weekly CMS publications since Jun 18, 2014.
What are the highest and lowest recorded NADAC prices for MORPHINE SULFATE ER 30 MG CAP?
Since Jun 18, 2014, the NADAC for MORPHINE SULFATE ER 30 MG CAP has ranged from a low of $4.4021 (May 18, 2016) to a high of $4.9125 (Nov 12, 2014), with a median of $4.6822 per EA.
Are there cheaper alternatives to MORPHINE SULFATE ER 30 MG CAP?
No other NADAC-published product currently shares the active ingredient and strength of MORPHINE SULFATE ER 30 MG CAP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures MORPHINE SULFATE ER 30 MG CAP?
MORPHINE SULFATE ER 30 MG CAP (NDC 00228309011) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.